Skip to main content

Search

Global Public Health

Global Public Health
global_public_health_website_image.jpg

As a healthcare partner, Janssen Pharmaceutical Companies of Johnson & Johnson is committed to protecting public health, especially during times of crisis.

Throughout our history, we have a track record of innovating solutions to alleviate disease and provide hope during some of humanity’s most testing times.

The COVID-19 pandemic is the perfect example, as a global emergency on a scale never-before-witnessed in modern times.

Janssen scientists matched the unprecedented nature of this crisis with their commitment to rapid innovation of treatment and prevention measures. Leveraging our proprietary AdVac® technology, we were able to develop and produce at scale a COVID-19 vaccine. Collaboration was also key; we partnered with governments and health authorities to enable broad, accelerated access to our innovation with the goal of ending the pandemic as quickly as possible.  

The pace of our COVID-19 response was borne out of our commitment to global public health. Today, we continue to fight infectious diseases affecting global populations, most notably tuberculosis (TB) and Ebola.

We are also working with the not-for-profit Drugs for Neglected Diseases initiative on the pre-clinical programme for a potential new treatment against parasites that cause elephantiasis and river blindness - two of the most difficult-to-treat neglected tropical diseases.

International Health Partners (IHP) - Medicines for those in need

We are proud to partner with IHP to donate products to vulnerable communities in disaster-hit regions of the world. IHP is working to eradicate suffering due to a lack of healthcare, by overseeing, co-ordinating and delivering strategic medical product donations to those most desperately in need.

CP-373118 l February 2023